Myotonic Dystrophy Type 2 Market

Market Overview:

The myotonic dystrophy type 2 market reached a value of USD 45.9 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 79.1 Million by 2035, exhibiting a growth rate (CAGR) of 5.28% during 2025-2035.

The myotonic dystrophy type 2 market has been comprehensively analyzed in IMARC's new report titled "Myotonic Dystrophy Type 2 Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Myotonic dystrophy type 2 is a genetic, autosomal dominant condition involving progressive muscle weakness, predominantly affecting muscles close to the middle of the body (proximal muscles). Myotonic dystrophy type 2 is usually a less severe condition than myotonic dystrophy type 1. The clinical presentation of this disease typically happens during the third or fourth decade, and the most frequent symptoms are muscle weakness, stiffness, and pain. The weakness tends to involve the proximal muscles of the shoulders and pelvis and causes trouble climbing stairs, combing and drying hair, and standing up from a chair. The affected persons may also have cardiac conduction defects, posterior subcapsular cataracts, and diabetes. Myotonic dystrophy type 2 is mainly diagnosed by combining clinical history, physical examination, and laboratory work. The health practitioner typically orders genetic testing to detect the existence of the unique genetic sequence causing the condition. In other situations, a muscle biopsy is also conducted to rule out a diagnosis and exclude other potential causes of underlying symptoms.

The escalating prevalence of mutation in the CNBP gene on chromosome 3, resulting in an unstable expansion of a segment of DNA called CCTG, is primarily driving the myotonic dystrophy type 2 market. In addition to this, the inflating utilization of sodium channel blockers, such as mexiletine, tricyclic antidepressants, benzodiazepines, etc., to reduce sustained myotonia and manage the symptoms of the disease is also creating a positive outlook for the market. Moreover, the rising usage of CPAP (continuous positive airway pressure) machine that can be used to treat sleep apnea in individuals with myotonic dystrophy type 2 is further bolstering the market growth. This procedure can help in managing breathing difficulties caused by respiratory muscle weakness associated with the condition. Apart from this, the widespread adoption of physical therapy, which includes tailored exercise programs to maintain muscle strength and range of motion in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of adeno-associated virus (AAV) genetic treatment, since it works by delivering a modified gene to muscle tissue using an AAV vector, aiming to counteract the effects of the genetic mutation causing the disease, is expected to drive the myotonic dystrophy type 2 market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the myotonic dystrophy type 2 market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for myotonic dystrophy type 2 and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the myotonic dystrophy type 2 market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the myotonic dystrophy type 2 market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the myotonic dystrophy type 2 market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current myotonic dystrophy type 2 marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the myotonic dystrophy type 2 market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the myotonic dystrophy type 2 market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the myotonic dystrophy type 2 market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of myotonic dystrophy type 2 across the seven major markets?
• What is the number of prevalent cases (2019-2035) of myotonic dystrophy type 2 by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of myotonic dystrophy type 2 by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with myotonic dystrophy type 2 across the seven major markets?
• What is the size of the myotonic dystrophy type 2 patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of myotonic dystrophy type 2?
• What will be the growth rate of patients across the seven major markets?

Myotonic Dystrophy Type 2: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for myotonic dystrophy type 2 drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the myotonic dystrophy type 2 market?
• What are the key regulatory events related to the myotonic dystrophy type 2 market?
• What is the structure of clinical trial landscape by status related to the myotonic dystrophy type 2 market?
• What is the structure of clinical trial landscape by phase related to the myotonic dystrophy type 2 market?
• What is the structure of clinical trial landscape by route of administration related to the myotonic dystrophy type 2 market?